Highlights from the 50th Annual Meeting of the European Association for the Study of the Liver include treatments that benefit a wider swath of the hep C population and those that reduce treatment time.
In the fast-changing field of hepatitis C virus (HCV) treatment, pharmaceutical companies are in a mad dash to develop improved therapies as they seek to tap into the hugely lucrative market. The annual International Liver Congress, which this year took place in Vienna, Austria, from April 22 to 26, gives a picture of what the future of hep C treatment may look like.
